RE:RE:RE:RE:RE:RE:Next MD &A
Steve, did you really just say that? the reason roger was sanction is because he said things were fda approved when they company hadn't even applied. there are specific timelines the FDA has to respond to a BTD application.
this is from November 2022, earlier in 2022 TLT said they expected "BTD approval" in q4 2022. Most of the "yes" men here say that BTD is a no brainer. TLT is is frequent contact w FDA due to fastr track. etc. The COVD excuse is over, all the company does is change the timeline on their website. Credibility, clarity and honesty has always been a challange for management, If they didn't meet the criteria to apply in q4 2022, i woud rather hear the truth than crickets. than at agm, they throw iout "any day", just like 5-7 years ago when roger said "they had the goods and were uplisting to nasdaq". Here we are 7 years later, stock price hasn;t change, management has accumlated a large percentage of the company but a stock option plan that doesn't reward performance, just a freee 10% every year no matter what they do... this wouldn;t fly in the US, lucky they are on TSX.
2) Break Through Designation Update. In 2021, Theralase® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 assessments for 25 patients, expected in 4Q2022,